CoChat

Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms

Open access
Scott, Aaron J., Arcaroli, John J., Bagby, Stacey M., Yahn, Rachel, Huber, Kendra M., Serkova, Natalie J., Nguyen, Anna, Kim, Jihye, Thorburn, Andrew, Vogel, Jon, Quackenbush, Kevin S., Capasso, Anna, Schreiber, Anna, Blatchford, Patrick, Klauck, Peter J., Pitts, Todd M., Eckhardt, S. Gail, Messersmith, Wells A. · 2018 · Molecular Cancer Therapeutics
Cited by 48

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Antiangiogenic therapy used in treatment of metastatic colorectal cancer (mCRC) inevitably succumbs to treatment resistance. Upregulation of MET may play an essential role to acquired anti-VEGF resistance. We previously reported that cabozantinib (XL184), an inhibitor of receptor tyrosine kinases (RTK) including MET, AXL, and VEGFR2, had potent antitumor effects in mCRC patient-derived tumor explant models. In this study, we examined the mechanisms of cabozantinib sensitivity, using regorafenib as a control. The tumor growth inhibition index (TGII) was used to compare treatment effects of cabozantinib 30 mg/kg daily versus regorafenib 10 mg/kg daily for a maximum of 28 days in 10 PDX mouse models. In vivo angiogenesis and glucose uptake were assessed using dynamic contrast-enhanced (DCE)-MRI and [18F]-FDG-PET imaging, respectively. RNA-Seq, RTK assay, and immunoblotting analysis were used to evaluate gene pathway regulation in vivo and in vitro. Analysis of TGII demonstrated significant antitumor effects with cabozantinib compared with regorafenib (average TGII 3.202 vs. 48.48, respectively; P = 0.007). Cabozantinib significantly reduced vascularity and glucose uptake compared with baseline. Gene pathway analysis showed that cabozantinib significantly decreased protein activity involved in glycolysis and upregulated proteins involved in autophagy compared with control, whereas regorafenib did not. The combination of two separate antiautophagy agents, SBI-0206965 and chloroquine, plus cabozantinib increased apoptosis in vitro. Cabozantinib demonstrated significant antitumor activity, reduction in tumor vascularity, increased autophagy, and altered cell metabolism compared with regorafenib. Our findings support further evaluation of cabozantinib and combinational approaches targeting autophagy in colorectal cancer. Mol Cancer Ther; 17(10); 2112–22. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-17-0131

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 48

Metadata

Authors
Scott, A. J., Arcaroli, J. J., Bagby, S. M., Yahn, R., Huber, K. M., Serkova, N. J., Nguyen, A., Kim, J., Thorburn, A., Vogel, J., Quackenbush, K. S., Capasso, A., Schreiber, A., Blatchford, P., Klauck, P. J., Pitts, T. M., Eckhardt, S. G., & Messersmith, W. A.
Venue
Molecular Cancer Therapeutics
Published
2018-10-01
Volume
17
Issue
10
Pages
2112-2122
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2883947220
Cited by
48
References
11
FWCI
1.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-0131
The paper
Scott, A. J., Arcaroli, J. J., Bagby, S. M., Yahn, R., Huber, K. M., Serkova, N. J., Nguyen, A., Kim, J., Thorburn, A., Vogel, J., Quackenbush, K. S., Capasso, A., Schreiber, A., Blatchford, P., Klauck, P. J., Pitts, T. M., Eckhardt, S. G., & Messersmith, W. A. (2018). Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.